Processa Pharmaceuticals (PCSA) CDO buys 1,971 shares in open-market trade

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Development Officer Sian Bigora reported an open-market purchase of 1,971 shares of common stock at $2.71 per share. Following this transaction, she directly holds 7,481 shares of common stock.

The filing also reports 267 shares of common stock held indirectly through CorLyst, LLC. A footnote states that shares were adjusted to correct immaterial errors, indicating minor corrections to previously reported share amounts.

Insider Trade Summary

Net Buyer: 1,971 shares ($5,341)

Net Buy 2 txns

Insider Bigora Sian

Role Chief Development Officer

Bought 1,971 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,971	$2.71	$5K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 7,481 shares (Direct, null); Common Stock — 267 shares (Indirect, By CorLyst, LLC)

Footnotes (1)

1. [object Object]

Key Figures

Open-market purchase: 1,971 shares Purchase price: $2.71/share Direct holdings after: 7,481 shares +2 more

5 metrics

Open-market purchase 1,971 shares Common Stock bought at $2.71 per share

Purchase price $2.71/share Price for 1,971-share open-market buy

Direct holdings after 7,481 shares Common Stock directly owned following purchase

Indirect holdings 267 shares Common Stock held indirectly by CorLyst, LLC

Net buy direction 1,971 shares net-buy Net of buys and sells in this filing

Key Terms

open-market purchase, indirect ownership, Form 4/A, Chief Development Officer, +1 more

5 terms

open-market purchase financial

"reported an open-market purchase of 1,971 shares of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"reports 267 shares of common stock held indirectly through CorLyst, LLC"

Form 4/A regulatory

"as disclosed in the Form 4/A filing"

Form 4/A is an amended filing that corrects or updates an earlier Form 4, the mandatory report that insiders (like company executives, directors, or large shareholders) must file when their ownership stakes change. Think of it as an edited receipt showing who bought or sold stock and when; investors use it to track insider confidence, detect potential conflicts, and spot trading patterns that might signal future company prospects.

Chief Development Officer financial

"Chief Development Officer Sian Bigora reported an open-market purchase"

Chief development officer is the senior executive who leads a company's efforts to create and grow future revenue streams, whether by developing new products, forging partnerships, or running clinical and regulatory programs in research-focused businesses. Investors watch this role because the officer shapes the pipeline and execution that determine future sales and risk — like a head gardener planning and tending crops that will produce tomorrow’s harvest.

immaterial errors financial

"A footnote states that shares were adjusted to correct immaterial errors"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bigora Sian

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
05/01/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/30/2026		P		1,971(1)	A	$2.71(1)	7,481(1)	D
Common Stock								267	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares adjusted to correct immaterial errors.

	/s/ Sian Bigora by John J. Wolfel, as Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA executive Sian Bigora report?

Sian Bigora reported buying 1,971 shares of Processa Pharmaceuticals common stock in an open-market transaction at $2.71 per share. This increased her directly held position to 7,481 shares, as disclosed in the Form 4/A filing.

How many Processa Pharmaceuticals (PCSA) shares does Sian Bigora now hold?

After the reported transaction, Sian Bigora directly holds 7,481 shares of Processa Pharmaceuticals common stock. The filing also shows 267 additional shares held indirectly through CorLyst, LLC, reflecting both her direct and indirect economic exposure.

Was the PCSA Form 4/A filing for a buy or sell transaction?

The Form 4/A filing reflects a buy transaction. It shows an open-market purchase of 1,971 shares of Processa Pharmaceuticals common stock at $2.71 per share, with no reported sales accompanying this purchase in the disclosed data.

At what price did the PCSA Chief Development Officer purchase shares?

The Chief Development Officer purchased Processa Pharmaceuticals common stock at a price of $2.71 per share. The transaction covered 1,971 shares, and this price applies to the entire reported open-market purchase in the amended Form 4 filing.

What does the indirect ownership entry for PCSA shares represent?

The filing lists 267 shares of Processa Pharmaceuticals common stock as indirectly owned by Sian Bigora through CorLyst, LLC. This indicates the shares are held via that entity, rather than in her name directly, but still count toward her reported beneficial holdings.

Why were Processa Pharmaceuticals (PCSA) share amounts adjusted in this Form 4/A?

A footnote explains that reported shares were adjusted to correct immaterial errors. This indicates small corrections to previously reported share counts, without suggesting any major change in ownership or additional transactions beyond those disclosed.